A phase 2, randomized, placebo-controlled, study evaluating the efficacy and safety of cendakimab (CC-93538) an anti- IL-13, in the treatment of moderate to severe AD, is still ongoing (69). This evidence concerns the gene IL13 and Alzheimer disease.